Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...
Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...
Of the thousands of books written by or about the Beatles and seemingly everyone in their orbit, it’s astonishing to think ...
The Fukushima Daiichi nuclear power plant’s radiation levels have significantly dropped since the cataclysmic meltdown 14 ...